TY  - BOOK
AU  - Barac, Ana
AU  - Gates, Emily
TI  - Trastuzumab-Induced Cardiomyopathy. [Review]
SN  - 0733-8651
PY  - 2019///
KW  - *Breast Neoplasms/dt [Drug Therapy]
KW  - *Cardiomyopathies/ci [Chemically Induced]
KW  - *Trastuzumab/ae [Adverse Effects]
KW  - Antineoplastic Agents, Immunological/ae [Adverse Effects]
KW  - Cardiomyopathies/ep [Epidemiology]
KW  - Cardiotoxicity
KW  - Female
KW  - Global Health
KW  - Humans
KW  - Incidence
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
KW  - Review
N2  - Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramatically improves HER2-positive breast cancer outcomes; however, its clinical use is associated with left ventricular dysfunction and heart failure. Patients receiving trastuzumab or other HER2-targeted therapies undergo routine cardiac function assessment. Holding and/or stopping trastuzumab treatment in the setting of left ventricular dysfunction is recommended. This article summarizes the role of trastuzumab in cancer treatment, the mechanisms of trastuzumab-induced cardiotoxicity, recent clinical investigations, and current controversies. Copyright (c) 2019 Elsevier Inc. All rights reserved
UR  - https://dx.doi.org/10.1016/j.ccl.2019.07.005
ER  -